OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Living with cancer· Appointment prep

Appointment sheet: Salivary duct carcinoma

One page to bring and write on: your details, the questions for Salivary duct carcinoma plus your own, the words you may hear, what to bring, the treatments the standard of care names, and room for the answers and agreed next steps. What you type stays in this browser. Print it or save it as a PDF. New to all this? Start with the first 60 days. Orientation, not medical advice.

Tick the questions to print

All of this cancer's questions start ticked. Untick what does not apply; ticks are kept in this browser. .

Your own questions

Shared with the prep pack, so questions you add there appear here too.

Print or save as PDF

Use (or Ctrl+P, Cmd+P on a Mac). To keep a copy, choose Save as PDF as the destination in the print dialog. Only the sheet prints; the controls stay on screen. Your typed notes print where you typed them; empty fields print as ruled lines to write on.

Appointment sheet

Salivary duct carcinoma

Prepared with OnCo (onco.cc/prep/salivary-duct-carcinoma/). Orientation, not medical advice; your team knows your case.

My details

Name
Date of appointment
Hospital and clinician
Who is coming with me

What I know, what is unclear, changes to discuss

Saved in this browser
What I know so far
What is unclear to me
Changes since last time

My questions

18 on the sheet
Newly diagnosed
  1. 1.What is my exact diagnosis, stage, and grade, and which tests established them?
  2. 2.Which biomarkers have been tested on my tumour (for example Androgen receptor immunohistochemistry, HER2 immunohistochemistry and in situ hybridisation, TP53, PIK3CA and HRAS mutations, PD-L1 and tumour mutational burden, Extranodal extension and margin status), and what were the results?
  3. 3.Which subtype is my cancer, and does that change the recommended treatment?
  4. 4.Is germline (inherited) genetic testing recommended for me or my family?
Localised, resectable
  1. 5.For my situation (localised, resectable), which of the standard options do you recommend and why?
  2. 6.Am I a candidate for Cisplatin, and what side effects should I expect?
HER2-positive recurrent or metastatic
  1. 7.For my situation (her2-positive recurrent or metastatic), which of the standard options do you recommend and why?
  2. 8.Am I a candidate for Trastuzumab, Docetaxel, Trastuzumab deruxtecan, and what side effects should I expect?
Androgen receptor-positive recurrent or metastatic
  1. 9.For my situation (androgen receptor-positive recurrent or metastatic), which of the standard options do you recommend and why?
  2. 10.Am I a candidate for Leuprolide (leuprorelin) and GnRH agonists, Bicalutamide, Enzalutamide or related drugs, and what side effects should I expect?
  3. 11.How do the results of A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma apply to someone like me?
Marker-negative or after targeted treatment
  1. 12.For my situation (marker-negative or after targeted treatment), which of the standard options do you recommend and why?
  2. 13.Am I a candidate for Cisplatin, Carboplatin, Paclitaxel / nab-paclitaxel or related drugs, and what side effects should I expect?
Any stage
  1. 14.Are there clinical trials I could join, for example of Trastuzumab deruxtecan, Apalutamide, A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma, Enzalutamide?
  2. 15.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
  3. 16.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
  4. 17.I read that “Almost all responses to targeted treatment are followed by relapse”. How does that affect my plan?
  5. 18.I read that “Whether to give anti-HER2 or anti-androgen treatment first when both targets are present”. How does that affect my plan?

The words I may hear

  • Extranodal extension (ENE): Extranodal extension means cancer in a lymph node has burst through the node's capsule into the surrounding fat; in head and neck cancer it is the single finding after surgery that most often turns radiotherapy into chemoradiotherapy, and in HPV-negative disease it moves the stage up.
  • Chemoradiation (chemoradiotherapy, CRT): Radiotherapy given at the same time as chemotherapy, which sensitises the cancer to radiation.

Tests and results to bring

Biomarker results to ask for: Androgen receptor immunohistochemistry, HER2 immunohistochemistry and in situ hybridisation, TP53, PIK3CA and HRAS mutations, PD-L1 and tumour mutational burden (usually low), Extranodal extension and margin status.

Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.

The treatments I may be offered

From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.

Answers and next steps

Saved in this browser
What I was told
Agreed next steps, dates and who to call